Australian (ASX) Healthcare Sector Analysis

Sector Valuation and Performance

Has the Australian Healthcare Sector valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 07 Jul 2026	AU$176.8b	AU$78.5b	AU$2.0b	26.1x	89.3x	2.3x
Thu, 04 Jun 2026	AU$148.9b	AU$77.6b	AU$1.8b	23.3x	82.8x	1.9x
Sat, 02 May 2026	AU$162.5b	AU$77.5b	AU$1.9b	26.9x	84.2x	2.1x
Mon, 30 Mar 2026	AU$172.1b	AU$78.8b	AU$2.0b	25.4x	85.8x	2.2x
Wed, 25 Feb 2026	AU$182.0b	AU$73.4b	AU$2.2b	24.3x	83.9x	2.5x
Fri, 23 Jan 2026	AU$214.7b	AU$73.4b	AU$4.4b	32.5x	48.4x	2.9x
Sun, 21 Dec 2025	AU$215.0b	AU$74.2b	AU$4.6b	32.9x	47.2x	2.9x
Tue, 18 Nov 2025	AU$220.0b	AU$74.7b	AU$4.6b	32.2x	47.6x	2.9x
Thu, 16 Oct 2025	AU$244.6b	AU$74.9b	AU$4.6b	31.2x	53.1x	3.3x
Sat, 13 Sep 2025	AU$239.7b	AU$74.3b	AU$4.5b	32x	52.9x	3.2x
Mon, 11 Aug 2025	AU$269.2b	AU$70.1b	AU$4.8b	37.3x	56.1x	3.8x
Wed, 09 Jul 2025	AU$262.4b	AU$71.6b	AU$4.3b	28.3x	61.6x	3.7x
Fri, 06 Jun 2025	AU$257.2b	AU$71.8b	AU$4.3b	26.2x	60.2x	3.6x
Sun, 04 May 2025	AU$260.7b	AU$70.5b	AU$4.9b	29.1x	53.6x	3.7x
Tue, 01 Apr 2025	AU$248.6b	AU$71.3b	AU$4.9b	27.5x	50.3x	3.5x
Thu, 27 Feb 2025	AU$270.5b	AU$66.9b	AU$4.4b	29.1x	60.8x	4x
Sat, 25 Jan 2025	AU$247.0b	AU$68.5b	AU$3.3b	26.3x	74.4x	3.6x
Mon, 23 Dec 2024	AU$240.8b	AU$68.8b	AU$3.3b	25.5x	72x	3.5x
Wed, 20 Nov 2024	AU$236.1b	AU$68.0b	AU$3.2b	26.3x	73.5x	3.5x
Fri, 18 Oct 2024	AU$246.2b	AU$67.3b	AU$3.1b	26.4x	79.5x	3.7x
Sun, 15 Sep 2024	AU$241.7b	AU$67.1b	AU$3.1b	27x	77.8x	3.6x
Tue, 13 Aug 2024	AU$241.8b	AU$63.0b	AU$2.6b	29.6x	91.3x	3.8x
Thu, 11 Jul 2024	AU$235.9b	AU$62.5b	AU$2.6b	32.7x	91.5x	3.8x
Sat, 08 Jun 2024	AU$231.4b	AU$63.0b	AU$2.6b	30x	88x	3.7x
Mon, 06 May 2024	AU$221.9b	AU$61.2b	AU$2.6b	27.3x	84.5x	3.6x
Wed, 03 Apr 2024	AU$227.9b	AU$61.6b	AU$2.7b	26.9x	85.3x	3.7x
Fri, 01 Mar 2024	AU$226.6b	AU$61.4b	AU$2.6b	25.7x	88x	3.7x
Sun, 28 Jan 2024	AU$228.3b	AU$60.5b	AU$2.8b	25.3x	80.1x	3.8x
Tue, 26 Dec 2023	AU$222.3b	AU$59.7b	AU$2.7b	24.9x	81.3x	3.7x
Thu, 23 Nov 2023	AU$202.9b	AU$60.5b	AU$2.9b	24.5x	70.4x	3.4x
Sat, 21 Oct 2023	AU$187.0b	AU$61.4b	AU$3.0b	24.9x	62x	3x
Mon, 18 Sep 2023	AU$209.1b	AU$61.2b	AU$2.9b	25.3x	72.4x	3.4x
Wed, 16 Aug 2023	AU$214.8b	AU$60.9b	AU$3.1b	26.1x	68.3x	3.5x
Fri, 14 Jul 2023	AU$210.4b	AU$57.2b	AU$2.8b	27.4x	74.8x	3.7x

Current Industry PE

Investors are optimistic on the Australian Healthcare industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 88.0x which is higher than its 3-year average PE of 70.8x.

The 3-year average PS ratio of 3.3x is higher than the industry's current PS ratio of 2.2x.

Past Earnings Growth

The earnings for companies in the Healthcare industry have declined 11% per year over the last three years.
Meanwhile revenues for these companies have grown 11% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Australian Healthcare sector?


AU Market	0.16%
Healthcare	5.00%
Healthtech	8.37%
Biotech	7.22%
Life Sciences	6.48%
Pharma	6.05%
Medical Equipment	5.15%
Healthcare Services	0.85%

Industry PE

Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 2kx.

Analysts are expecting annual earnings growth of 4.3%, which is lower than the prior year's growth of 92.7% per year.

Forecasted Growth

Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 46% over the next 5 years.
This is better than its past earnings decline of 60% per year.

In contrast, the Healthtech industry is expected to see its earnings grow by 4.3% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
CSL CSL	AU$123.97	8.0% +AU$4.4b	-49.6%	PE29.5x
SIG Sigma Healthcare	AU$2.82	2.5% +AU$805.2m	-5.7%	PE54.1x
PME Pro Medicus	AU$210.74	3.6% +AU$763.7m	-32.9%	PE93.8x
SHL Sonic Healthcare	AU$21.86	5.0% +AU$518.8m	-18.7%	PE20x
COH Cochlear	AU$127.05	4.4% +AU$346.6m	-57.9%	PE24.1x

Telix Pharmaceuticals Aligns with Fda to Advance Prostact Global Phase 3 Trial

Telix Pharmaceuticals announced the successful outcome of a Type B meeting with the United States Food and Drug Administration to review the Part 1 safety and dosimetry data and Part 2 protocol design of the ProstACT Global Phase 3 trial of its therapeutic candidate TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in metastatic castration resistant prostate cancer. The FDA has confirmed that the safety data from Part 1 of the study is sufficient to enable progression of Part 2 of ProstACT Global into the U.S. in which TLX591-Tx is administered in two doses, 14 days apart, in combination with one of three randomized standard of care therapies: abiraterone, enzalutamide or docetaxel. The FDA and Telix also achieved alignment on the Part 2 clinical trial protocol, statistical analysis plan, and ongoing safety monitoring plan. The result is a consistent framework for study execution as enrollment continues internationally and expands into the U.S. Initiation of Part 2 in the U.S. remains subject to the FDA’s review of an Investigational New Drug amendment. The amendment will also be aligned with a pending regulatory submission to initiate the ProstACT Global study in Europe. The trial continues to enroll patients in regions where Part 2 is approved. ProstACT Global (ClinicalTrials.gov ID: NCT06520345) is an international, multicenter trial in two parts: Part 1, safety and dosimetry lead-in with 36 patients (complete); and Part 2, 2:1 randomized global expansion with an overall target enrollment of approximately 490 patients. Eligible patients must have confirmed progressive mCRPC assessed with a 68Ga-PSMA-11 PET imaging agent (such as Illuccix, kit for the preparation of gallium-68 (68Ga) gozetotide injection, or Gozellix, kit for the preparation of gallium-68 (68Ga) gozetotide injection) following prior treatment with one ARPI. The antibody-based approach demonstrates differentiated targeting and pharmacology to other PSMA-targeted small molecule radioligand therapies. In contrast to these therapies, collective long-term follow-up of patients administered with TLX591-Tx has not observed significant acute or delayed kidney toxicity, as the agent is hepatically (liver) excreted, a comparatively radioresistant organ. TLX591-Tx also demonstrates minimal salivary and lacrimal gland uptake, reducing the prevalence of xerostomia (dry mouth) and dry eye, which are typical adverse effects of existing PSMA-targeted radioligand therapies. Part 2 is enrolling in Australia, New Zealand, Canada, Türkiye, and the United Kingdom, and has also received regulatory approval to commence in China, Singapore and South Korea.

Australian (ASX) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Consensus EPS estimates fall by 12%

Growth Investors: Industry Analysts Just Upgraded Their Neuren Pharmaceuticals Limited (ASX:NEU) Revenue Forecasts By 55%

ARX: Higher Multiple And Earnings Outlook Will Support Future Upside

Mesoblast Reaches Key Patient Milestone and Funding for Pivotal Back Pain Study

Sigma Healthcare Limited to Report Fiscal Year 2026 Results on Aug 27, 2026

SHL: Higher Discount Rate Will Pressure Future Earnings Multiple

Telix Pharmaceuticals Aligns with Fda to Advance Prostact Global Phase 3 Trial

CSL Launches Major Restructuring With Seqirus Spin-Off and CEO Search Following Profit Warnings

COH: Hospital Bottlenecks And Weaker Referrals Will Pressure Earnings Expectations

Now 20% undervalued

Forecast to breakeven in 2029

Forecast to breakeven in 2029

4DMedical Wins TGA Approval to Commercialize CT:VQ Lung Imaging Across Australia

New minor risk - Share price stability

Here's Why We're Not Too Worried About Nyrada's (ASX:NYR) Cash Burn Situation

CEO, MD & Executive Director recently sold AU$1.1m worth of stock